PALISADE BIO, INC. (PALI)
About PALISADE BIO, INC.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2024
- $0
- Net income
- -$16.8M
- Total assets
- $134.3M
- Market cap
- $338.9M
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $338.9M
- Shares outstanding
- 282.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 28, 2021
Palisade BIO, Inc. (PALI) Stock Price
- Reported a net loss of $16.8M in FY2024.
- Trading 57% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review PALISADE BIO, INC..
Write a review
News about PALISADE BIO, INC.
News & sentiment via Polygon.io
Palisade BIO, Inc.: frequently asked questions
Is Palisade BIO, Inc. an American company?
Palisade BIO, Inc. is a US-based company headquartered in Carlsbad, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Palisade BIO, Inc. headquartered?
Palisade BIO, Inc. is headquartered in Carlsbad, California, United States.
Is Palisade BIO, Inc. publicly traded?
Yes — Palisade BIO, Inc. is a publicly traded company. Its stock trades under the ticker symbol PALI on the NASDAQ.
What does Palisade BIO, Inc. do?
Palisade BIO, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
